AAV Gene Therapy for Stable Factor IX Levels in Hemophilic Joints
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing gene therapy approaches for hemophilia fail to establish long-term expression of the missing coagulation factors, leading to peaks and troughs in factor activity levels that cause irreversible joint damage known as hemophilic arthropathy.
Innovation Solution
A gene therapy vehicle using AAV-based vectors to deliver codon-optimized nucleic acids encoding coagulation factors, such as Factor IX or VIII, to achieve a steady and elevated activity level, minimizing fluctuations and preventing joint damage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If regular protein replacement therapy is used to treat hemophilia, then bleeding episodes can be controlled, but peaks and troughs in factor activity levels cause internal joint bleeding leading to hemophilic arthropathy
Solution Approach 1:
The patent applies gene therapy to achieve continuous expression of coagulation factors, eliminating the periodic administration required by protein replacement therapy. This continuous expression maintains stable factor activity levels without peaks and troughs, preventing internal joint bleeding while ensuring reliable control of bleeding episodes.
Solution Approach 2:
The patent enables the patient's own cells to produce the missing coagulation factors through gene therapy. The introduced gene integrates into the patient's genome and directs endogenous production of functional factors, making the patient self-sufficient rather than requiring external protein replacement.
2Object-affected harmful factors
If gene therapy is used to achieve constant factor levels, then joint damage can be prevented, but early approaches failed to establish long-term expression
Solution Approach 1:
The patent optimizes multiple parameters of the gene therapy system including selecting specific viral vectors (AAV serotypes), optimizing promoter elements, modifying codon usage for enhanced expression, and adjusting dosing regimens. These parameter optimizations collectively achieve both long-term persistence and stable expression levels of the transgene.
Solution Approach 2:
The patent employs strategies to monitor and adjust gene therapy outcomes, including assessing transgene expression levels, factor activity measurements, and adjusting treatment parameters based on observed efficacy and persistence to optimize long-term expression stability.
Data Source
AI summary
The invention relates to a gene therapy vehicle for use in preventing, arresting and/or treating hemophilic arthropathy of a joint in a patient having hemophilia B, where the gene therapy vehicle comprises a nucleic acid that encodes a coagulation factor having Factor IX activity.